Second quarter April - June 2021
• Net sales: 0 (0) TSEK.
• Other operating income: 839 (2161) TSEK.
• Profit after financial items: -15 402 (-4 389) TSEK.
• Earnings per share: -0.06 (-0.04) SEK.

Period January - June 2021
• Net sales: 0 (0) TSEK.
• Other operating income: 5 957 (6 219) TSEK.
• Profit after financial items: -26 258 (-12 055) TSEK.
• Earnings per share: SEK -0.11 (-0.11).
• Liquidity at the end of the period: 82 376 (18 026) TSEK.
• End-of-period equity/assets ratio: 97 (71) %.

Events during the period
• CombiGene completes a fully guaranteed rights issue providing the company with approximately SEK 75 million before issue costs.
• On May 25, 2021, CombiGene AB held its Annual General Meeting (AGM) in Lund. The AGM resolved all matters in accordance with the proposal of the Board of Directors and the Nomination Committee. The AGM resolved to re-elect Peter Nilsson, Bert Junno, Jonas Ekblom and Per Lundin as Board members and to elect Gunilla Lundmark as new member of the Board. Bert Junno was also re-elected Chairman of the Board. Mazars AB was re-elected as auditor. The AGM resolved, in accordance with the Nomination Committee’s proposal, on board fees and that auditor’s fees shall be paid in accordance with approved invoices. The AGM further resolved to merge the company’s shares, with twenty (20) existing shares being combined into one (1) new share (aggregation 1:20). The AGM also resolved to amend the Articles of Association in such a way that the Board of Directors shall have its registered office in Stockholm, instead of Lund, Skåne County.
• CombiGene and Neurochase initiated the work of optimizing the administration of CG01 in a preclinical study. The results of the study are expected to be completed in late summer 2021 and a positive outcome will mean that long-term studies in toxicology and biodistribution in large animals can start as planned.
• The plasmids to be used in the GMP production of CG01 have been manufactured and subjected to the usual quality assurance. The plasmids will be used as starting material for the GMP batch that will be used in the first clinical study scheduled to begin in 2022.

Events after the end of the period
• GMP production of CG01 for the first human study.
• CG01 gets patents in the U.S. and Russia.

Link to the report

Contacts

Jan Nilsson, CEO
Phone: +46 (0)704 66 31 63
jan.nilsson@combigene.com

Bert Junno, Chairman of the board
Phone: +46 (0)707 77 22 09
bert.junno@combigene.com

www.combigene.com
CombiGene AB (publ) Medicon Village, SE-223 81 Lund, Sweden
info@combigene.com

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies.

CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99, info@fnca.se.

CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 823282.
CombiGene´s project CGT2 is supported by the Eurostars Programme. Project ID: 114714.

Attachments

CombiGene Q2 2021 EN

© Modular Finance, source Nordic Press Releases